Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2018

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Japan Agreement were as follows (in thousands):

		Three Months Ended March 31,
Agreement	Performance Obligation	2018		2017 *
Japan	License revenue	$	—	$	—
	Development revenue	$	449	$	296

*	Recast to reflect the adoption of the new revenue standards. See Note 1.

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through March 31, 2018		Deferred Revenue at March 31, 2018		Total Consideration Through March 31, 2018
License	$	59,766	$	—	$	59,766
Manufacturing--clinical supplies		11,957		436		12,393
Total license and development revenue	$	71,723	$	436	$	72,159

Europe [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

		Three Months Ended March 31,
Agreement	Performance Obligation	2018		2017 *
Europe	License revenue	$	—	$	—
	Development revenue	$	4,723	$	4,390

*	Recast to reflect the adoption of the new revenue standards. See Note 1.

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through March 31, 2018		Deferred Revenue at March 31, 2018		Total Consideration Through March 31, 2018
License	$	370,481	$	—	$	370,481
Manufacturing--clinical supplies		189,056		6,101		195,157
Total license and development revenue	$	559,537	$	6,101	$	565,638

U.S./RoW and China [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands):

		Three Months Ended March 31,
Agreement	Performance Obligation	2018		2017 *
U.S. / RoW and China	License revenue	$	—	$	—
	Development revenue		26,723		24,756
	China performance obligation	$	—	$	—

*	Recast to reflect the adoption of the new revenue standards. See Note 1.

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through March 31, 2018		Deferred Revenue at March 31, 2018		Total Consideration Through March 31, 2018
License	$	286,216	$	—	$	286,216
Co-development, information sharing & committee services		330,391		36,360		366,751
China performance obligation		—		112,009		112,009
Total license and development revenue	$	616,607	$	148,369	$	764,976